NRW.Bank

DGAP-News: AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital

Retrieved on: 
Monday, March 14, 2022

AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital

Key Points: 
  • AYOXXA receives fresh capital for commercial growth in Europe, US and Asia led by Prosnav Capital
    The issuer is solely responsible for the content of this announcement.
  • The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network.
  • "We are proud to have attracted Prosnav Capital as a shareholder.
  • "With our LUNARIS(TM) platform, AYOXXA is well positioned to enter the commercial growth phase."

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Retrieved on: 
Thursday, October 21, 2021

Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Key Points: 
  • Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.
  • This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class.
  • Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.
  • Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers.

DGAP-News: BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost! 2021

Retrieved on: 
Wednesday, October 6, 2021

BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!

Key Points: 
  • BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!
  • BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!
  • Oktober 2021: For the eighth time in a row the annual start-up competition for life science and biotech founders, BioRiver Boost!, honored the best start-up companies in the industry on October 1, 2021.
  • Since 2014, the industry association BioRiver organizes BioRiver Boost!, the competition for life science founders.